{"nctId":"NCT00180479","briefTitle":"SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)","startDateStruct":{"date":"2005-06"},"conditions":["Stents","Coronary Artery Disease","Total Coronary Occlusion","Coronary Artery Restenosis","Stent Thrombosis","Vascular Disease","Myocardial Ischemia","Coronary Artery Stenosis"],"count":1002,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Device: XIENCE V® Everolimus Eluting Coronary Stent"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Device: TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent"]}],"interventions":[{"name":"XIENCE V® Everolimus Eluting Coronary Stent","otherNames":["XIENCE V® Everolimus Eluting Coronary Stent System"]},{"name":"TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent","otherNames":["TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Target lesion(s) must be located in a native epicardial vessel with visually estimated diameter between \\>= 2.25 mm and \\<= 4.25 mm and a lesion length \\<= 32 mm\n* The target lesion(s) must be in a major artery or branch with a visually estimated stenosis of \\>= 50% and \\< 100% with a thrombolysis in myocardial infarction (TIMI) flow of \\>= 1\n* Non-study, percutaneous intervention for lesions in a non-target vessel is allowed if done \\>= 90 days prior to the index procedure (subjects who received brachytherapy will be excluded from the trial)\n\nExclusion Criteria:\n\n* Located within an arterial or saphenous vein graft or distal to a diseased (vessel irregularity per angiogram and \\> 20% stenosed lesion by visual estimation) arterial or saphenous vein graft\n* Lesion involving a bifurcation \\>= 2 mm in diameter or ostial lesion \\> 50% stenosed by visual estimation or side branch requiring predilatation\n* Located in a major epicardial vessel that has been previously treated with brachytherapy\n* Located in a major epicardial vessel that has been previously treated with percutaneous intervention \\< 9 months prior to index procedure\n* Total occlusion (TIMI flow 0), prior to wire passing\n* The target vessel contains thrombus\n* Another significant lesion (\\> 40% diameter stenosis \\[DS\\]) is located in the same epicardial vessel as the target lesion","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Primary Endpoint: In-segment Late Loss (LL)","description":"In-segment minimal lumen diameter (MLD) post-procedure minus (-) in segment MLD at 240 day follow-up and 5 mm proximal and 5mm distal to the stent equals Late Loss. MLD defined: The average of two orthogonal views (when possible) of the narrowest point within the area of assessment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"0.41"},{"groupId":"OG001","value":"0.28","spread":"0.48"}]}]}]},{"type":"SECONDARY","title":"Major Secondary Endpoint: Ischemia Driven Target Vessel Failure (ID-TVF)","description":"The composite endpoint comprised of:\n\n* Cardiac death (death in which a cardiac cause cannot be excluded)\n* Myocardial infarction (MI, classified as Q-wave and non-Q wave)\n* Ischemia-driven target lesion revascularization (TLR) by CABG or PCI\n* Ischemia-driven target vessel revascularization (TVR) by CABG or PCI","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":null},{"groupId":"OG001","value":"9.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Target Vessel Failure (TVF)","description":"The composite endpoint comprised of:\n\n* Cardiac death (death in which a cardiac cause cannot be excluded)\n* Myocardial infarction (MI, classified as Q-wave and non-Q wave)\n* Ischemia-driven target lesion revascularization (TLR) by CABG or PCI\n* Ischemia-driven target vessel revascularization (TVR) by CABG or PCI","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Target Vessel Failure (TVF)","description":"The composite endpoint comprised of:\n\n* Cardiac death (death in which a cardiac cause cannot be excluded)\n* Myocardial infarction (MI, classified as Q-wave and non-Q wave)\n* Ischemia-driven target lesion revascularization (TLR) by CABG or PCI\n* Ischemia-driven target vessel revascularization (TVR) by CABG or PCI","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"5.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Target Vessel Failure (TVF)","description":"The composite endpoint comprised of:\n\n* Cardiac death (death in which a cardiac cause cannot be excluded)\n* Myocardial infarction (MI, classified as Q-wave and non-Q wave)\n* Ischemia-driven target lesion revascularization (TLR) by CABG or PCI\n* Ischemia-driven target vessel revascularization (TVR) by CABG or PCI","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"11.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Target Vessel Failure (TVF)","description":"The composite endpoint comprised of:\n\n* Cardiac death (death in which a cardiac cause cannot be excluded)\n* Myocardial infarction (MI, classified as Q-wave and non-Q wave)\n* Ischemia-driven target lesion revascularization (TLR) by CABG or PCI\n* Ischemia-driven target vessel revascularization (TVR) by CABG or PCI","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":null},{"groupId":"OG001","value":"16.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Target Vessel Failure (TVF)","description":"The composite endpoint comprised of:\n\n* Cardiac death (death in which a cardiac cause cannot be excluded)\n* Myocardial infarction (MI, classified as Q-wave and non-Q wave)\n* Ischemia-driven target lesion revascularization (TLR) by CABG or PCI\n* Ischemia-driven target vessel revascularization (TVR) by CABG or PCI","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Target Vessel Failure (TVF)","description":"The composite endpoint comprised of:\n\n* Cardiac death (death in which a cardiac cause cannot be excluded)\n* Myocardial infarction (MI, classified as Q-wave and non-Q wave)\n* Ischemia-driven target lesion revascularization (TLR) by CABG or PCI\n* Ischemia-driven target vessel revascularization (TVR) by CABG or PCI","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":null},{"groupId":"OG001","value":"22.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Target Lesion Revascularization (ID-TLR)","description":"Revascularization @ target lesion associated w/ any of following:\n\n(+) functional ischemia study Ischemic symptoms \\& angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Target Lesion Revascularization (ID-TLR)","description":"Revascularization @ target lesion associated w/ any of following:\n\n(+) functional ischemia study Ischemic symptoms \\& angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Target Lesion Revascularization (ID-TLR)","description":"Revascularization @ target lesion associated w/ any of following:\n\n(+) functional ischemia study Ischemic symptoms \\& angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Target Lesion Revascularization (ID-TLR)","description":"Revascularization @ target lesion associated w/ any of following:\n\n(+) functional ischemia study Ischemic symptoms \\& angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"5.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Target Lesion Revascularization (ID-TLR)","description":"Revascularization @ target lesion associated w/ any of following:\n\n(+) functional ischemia study Ischemic symptoms \\& angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"9.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Target Lesion Revascularization (ID-TLR)","description":"Revascularization @ target lesion associated w/ any of following:\n\n(+) functional ischemia study Ischemic symptoms \\& angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"9.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Target Lesion Revascularization (ID-TLR)","description":"Revascularization @ target lesion associated w/ any of following:\n\n(+) functional ischemia study Ischemic symptoms \\& angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"10.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Target Vessel Revascularization (ID-TVR)","description":"Revascularization at the target vessel associated with any of the following\n\n* Positive functional ischemia study\n* Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA\n* Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study\n\nDerived from Non-Hierarchical Subject Counts of Adverse Events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Target Vessel Revascularization (ID-TVR)","description":"Revascularization at the target vessel associated with any of the following\n\n* Positive functional ischemia study\n* Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA\n* Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study\n\nDerived from Non-Hierarchical Subject Counts of Adverse Events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Target Vessel Revascularization (ID-TVR)","description":"Revascularization at the target vessel associated with any of the following\n\n* Positive functional ischemia study\n* Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA\n* Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study\n\nDerived from Non-Hierarchical Subject Counts of Adverse Events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Target Vessel Revascularization (ID-TVR)","description":"Revascularization at the target vessel associated with any of the following\n\n* Positive functional ischemia study\n* Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA\n* Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study\n\nDerived from Non-Hierarchical Subject Counts of Adverse Events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Target Vessel Revascularization (ID-TVR)","description":"Revascularization at the target vessel associated with any of the following\n\n* Positive functional ischemia study\n* Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA\n* Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study\n\nDerived from Non-Hierarchical Subject Counts of Adverse Events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":null},{"groupId":"OG001","value":"6.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Target Vessel Revascularization (ID-TVR)","description":"Revascularization at the target vessel associated with any of the following\n\n* Positive functional ischemia study\n* Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA\n* Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study\n\nDerived from Non-Hierarchical Subject Counts of Adverse Events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"8.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Target Vessel Revascularization (ID-TVR)","description":"Revascularization at the target vessel associated with any of the following\n\n* Positive functional ischemia study\n* Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA\n* Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study\n\nDerived from Non-Hierarchical Subject Counts of Adverse Events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null},{"groupId":"OG001","value":"9.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Major Adverse Cardiac Event (MACE)","description":"The composite endpoint comprised of:\n\n* Cardiac death\n* Myocardial infarction (MI, classified as Q-wave and non-Q wave)\n* Ischemia-driven target lesion revascularization (TLR) by CABG or PCI","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Major Adverse Cardiac Event (MACE)","description":"The composite endpoint comprised of:\n\n* Cardiac death\n* Myocardial infarction (MI, classified as Q-wave and non-Q wave)\n* Ischemia-driven target lesion revascularization (TLR) by CABG or PCI","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"5.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Major Adverse Cardiac Event (MACE)","description":"The composite endpoint comprised of:\n\n* Cardiac death\n* Myocardial infarction (MI, classified as Q-wave and non-Q wave)\n* Ischemia-driven target lesion revascularization (TLR) by CABG or PCI","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"8.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Major Adverse Cardiac Event (MACE)","description":"The composite endpoint comprised of:\n\n* Cardiac death\n* Myocardial infarction (MI, classified as Q-wave and non-Q wave)\n* Ischemia-driven target lesion revascularization (TLR) by CABG or PCI","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null},{"groupId":"OG001","value":"10.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Major Adverse Cardiac Event(MACE)","description":"The composite endpoint comprised of:\n\n* Cardiac death\n* Myocardial infarction (MI, classified as Q-wave and non-Q wave)\n* Ischemia-driven target lesion revascularization (TLR) by CABG or PCI","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"13.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Major Adverse Cardiac Event (MACE)","description":"The composite endpoint comprised of:\n\n* Cardiac death\n* Myocardial infarction (MI, classified as Q-wave and non-Q wave)\n* Ischemia-driven target lesion revascularization (TLR) by CABG or PCI","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null},{"groupId":"OG001","value":"16.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Major Adverse Cardiac Event (MACE)","description":"The composite endpoint comprised of:\n\n* Cardiac death\n* Myocardial infarction (MI, classified as Q-wave and non-Q wave)\n* Ischemia-driven target lesion revascularization (TLR) by CABG or PCI","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"18.5","spread":null}]}]}]},{"type":"SECONDARY","title":"In-stent % Angiographic Binary Restenosis (% ABR) Rate","description":"Percent of subjects with a follow-up in-stent percent diameter stenosis of ≥ 50% per quantitative coronary angiography (QCA)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]}]},{"type":"SECONDARY","title":"In-segment % Angiographic Binary Restenosis (% ABR) Rate","description":"Percent of subjects with a follow-up in-segment percent diameter stenosis of ≥ 50% per QCA","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"8.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Persisting Incomplete Stent Apposition, Late-acquired Incomplete Stent Apposition, Aneurysm, Thrombosis, and Persisting Dissection","description":"Incomplete Apposition (Persisting \\& Late acquired): Failure to completely appose vessel wall w/ ≥1 strut separated from vessel wall w/ blood behind strut per ultrasound. Aneurysm: Abnormal vessel expansion ≥ 1.5 of reference vessel diameter. Thrombus: Protocol \\& ARC definition.\n\nPersisting dissection @ follow-up, present post-procedure.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","spread":null},{"groupId":"OG001","value":"14.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Acute Success: Clinical Device","description":"Successful delivery and deployment of 1st implanted study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis \\< 50%.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null},{"groupId":"OG001","value":"98.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Acute Success: Clinical Procedure","description":"Successful delivery and deployment of study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis \\< 50%.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"97.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Proximal Late Loss","description":"Proximal Minimum Lumen Diameter (MLD) post-procedure minus proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to stent placement)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"0.40"},{"groupId":"OG001","value":"0.20","spread":"0.41"}]}]}]},{"type":"SECONDARY","title":"Distal Late Loss","description":"Distal MLD post-procedure minus distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to stent placement)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.36"},{"groupId":"OG001","value":"0.10","spread":"0.37"}]}]}]},{"type":"SECONDARY","title":"In-stent Late Loss","description":"In-stent MLD post-procedure minus in-stent MLD at follow-up (in-stent defined as within the margins of the stent)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.41"},{"groupId":"OG001","value":"0.30","spread":"0.53"}]}]}]},{"type":"SECONDARY","title":"% Volume Obstruction (% VO)","description":"Defined as stent intimal hyperplasia and calculated as 100\\*(Stent Volume - Lumen Volume)/Stent Volume by IVUS.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.91","spread":"6.35"},{"groupId":"OG001","value":"11.21","spread":"9.86"}]}]}]},{"type":"SECONDARY","title":"In-stent % Diameter Stenosis (% DS)","description":"In-stent: Within the margins of the stent, the value calculated as 100 \\* (1 - in-stent MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.92","spread":"16.40"},{"groupId":"OG001","value":"10.30","spread":"21.43"}]}]}]},{"type":"SECONDARY","title":"In-segment % Diameter Stenosis (% DS)","description":"Within the margins of the stent, 5 mm proximal and 5 mm distal to the stent, the value calculated as 100 \\* (1 - in-segment MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.77","spread":"14.43"},{"groupId":"OG001","value":"22.82","spread":"16.35"}]}]}]},{"type":"SECONDARY","title":"Target Vessel Failure (TVF)","description":"The composite endpoint comprised of:\n\n* Cardiac death (death in which a cardiac cause cannot be excluded)\n* Myocardial infarction (MI, classified as Q-wave and non-Q wave)\n* Ischemia-driven target lesion revascularization (TLR) by CABG or PCI\n* Ischemia-driven target vessel revascularization (TVR) by CABG or PCI","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.3","spread":null},{"groupId":"OG001","value":"26.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Target Lesion Revascularization (ID-TLR)","description":"Revascularization @ target lesion associated w/ any of following:\n\n(+) functional ischemia study Ischemic symptoms \\& angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":null},{"groupId":"OG001","value":"12.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Target Vessel Revascularization (ID-TVR)","description":"Revascularization at the target vessel associated with any of the following\n\n* Positive functional ischemia study\n* Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA\n* Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study\n\nDerived from Non-Hierarchical Subject Counts of Adverse Events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":null},{"groupId":"OG001","value":"11.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Ischemia Driven Major Adverse Cardiac Event (MACE)","description":"The composite endpoint comprised of:\n\n* Cardiac death\n* Myocardial infarction (MI, classified as Q-wave and non-Q wave)\n* Ischemia-driven target lesion revascularization (TLR) by CABG or PCI","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":null},{"groupId":"OG001","value":"22.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":219},"commonTop":["Angina pectoris","Catheter site haematoma","Myocardial infarction"]}}}